When you have advanced prostate cancer: What living with the disease looks like
Living With Advanced Prostate Cancer: A Modern Perspective
Activelifezero.com – When Dr. Jamin Brahmbhatt, a urologist and robotic surgeon affiliated with Orlando Health and the University of Central Florida’s College of Medicine, shares a prostate cancer diagnosis with his patients, one question consistently rises to the surface. “How long do I have to live?” This inquiry typically comes first, reflecting the deep concern that accompanies such news. For individuals with early-stage or low-grade disease, Brahmbhatt offers considerable reassurance. The five-year relative survival rate exceeds 99% with appropriate treatment, meaning the vast majority of men will not succumb to this form of cancer.
However, the prognosis shifts considerably once the malignancy extends beyond the prostate gland into the skeletal system and other vital organs. Over the last ten years, therapeutic approaches for advanced cases have undergone remarkable transformation. Enhanced imaging technologies, novel pharmaceutical agents, and the strategic deployment of combination therapies are enabling patients to extend their lifespans significantly.
A Public Case Study: President Biden’s Journey
In May 2025, former President Joe Biden publicly disclosed his diagnosis of an aggressive variant of prostate cancer that had metastasized to his bones. This announcement generated substantial media attention and renewed conversations about screening protocols and treatment options. According to official statements, his malignancy carries a Gleason score of 9, placing it within the most aggressive classification. The score, determined by a pathologist examining biopsy specimens, ranges from 6 to 10, with elevated numbers signaling greater severity.
Since his initial diagnosis, Biden has remained engaged in hormone therapy, completed a radiation treatment course, and maintained an active public role. A video message released on July 15 provided further updates, noting that his treatments have proceeded favorably. His case has become a valuable reference point for understanding contemporary management of metastatic disease.
Beyond the Statistics
Many patients turn to the internet seeking survival data, yet the numbers they encounter often carry important caveats. The American Cancer Society cites a five-year relative survival rate above 99% for cancers confined to or near the prostate. When the disease reaches distant locations, that figure decreases to 38%. Yet this statistic derives from historical cohorts and does not fully capture the influence of modern interventions or individual variables such as age, general health, and therapeutic response.
“Survival statistics describe groups of patients but do not predict what will happen to one person. That is why the 38% figure cannot tell us how long Biden — or any individual patient — will live.”
The outlook for metastatic patients hinges on specific characteristics of their cancer and their personal response to available treatments. Common sites for metastasis include the spine, pelvis, and ribs, though the lungs and liver can also be affected. While distant spread generally precludes a complete cure, contemporary therapies can effectively slow progression for many years.
Evolution of Treatment Strategies
A patient diagnosed with metastatic prostate cancer ten years ago would likely have received a different treatment regimen than someone diagnosed today. Historically, physicians initiated hormone therapy—typically involving injections that reduce testosterone levels—and reserved additional interventions for when the disease became resistant. Current practice favors deploying the most effective treatments earlier rather than conserving them.
Today, hormone injections are frequently combined from the outset with newer hormone-blocking medications and sometimes chemotherapy. These integrated approaches have contributed substantially to improved survival outcomes and represent one of the most significant advances in urologic oncology over the past decade.
Quality of Life Matters
Beyond survival metrics, maintaining daily functionality remains crucial. Brahmbhatt recently treated a patient diagnosed three years prior with cancer that had already disseminated to several bone regions. Despite the advanced nature of his condition, this individual continues to enjoy cruises, family travel, and weekend childcare for his grandchildren. He experiences fatigue and no longer gardens as vigorously as before, yet he regards each day as a gift.
This patient’s experience, alongside Biden’s public journey, illustrates what living with metastatic prostate cancer can resemble in the current era. The combination of earlier intervention, improved medications, and comprehensive care has transformed what was once considered a terminal prognosis into a manageable chronic condition for many men.
As global projections indicate that cancer-related deaths among men could rise by 93% by 2050, understanding these advances becomes increasingly vital. The evolution of prostate cancer treatment demonstrates that a diagnosis, even an aggressive one, no longer necessarily means the end of an active, fulfilling life.
